Navigation Links
Biomoda Hires Senior Scientist to Expand Research & Development Effort
Date:1/11/2008

ALBUQUERQUE, N.M., Jan. 11 /PRNewswire-FirstCall/ -- Biomoda, Inc. (OTC Bulletin Board: BMOD) (http://www.biomoda.com) of Albuquerque, NM, announced today Dr. Stephen M. Gomez has joined Biomoda as a Senior Research Specialist focused on the company's efforts to commercialize its assay for the early detection of lung cancer.

Dr. Gomez most recently worked as an associate research scientist at Lovelace Respiratory Research Institute in Albuquerque. He was an instructor in genetics at the University of New Mexico and consultant to national laboratories and UCLA. He is the author of nearly a dozen publications on proteomics and photosystems including his dissertation at the University of California, Los Angeles, on pigment-binding proteins.

"Dr. Gomez's experience and expertise in molecular, cell and development biology is of particular importance and use at Biomoda where we have developed a mechanism that preferentially binds to cancer cells and glows red under a microscope for easy and accurate detection of the disease," explained John Cousins, President of Biomoda. "I am pleased to have him working side-by-side with our team of exceptional scientists in the development and application of our assay by the medical community."

Dr. Gomez was awarded a Masters of Biology by the University of California before going on the get his Ph.D. in Molecular, Cell and Development Biology from the same institution. He holds a bachelors degree in biology from the California Institute of Technology, Pasadena.

Biomoda's patented technology, a non-invasive cytology based assay, is designed for cancer screening of large populations at a reasonable cost. Current diagnostic methods for lung cancer, including CT scans and X-rays, often detect the disease only at more advanced stages and are relatively expensive.

Lung cancer claims more lives than any other cancer. The expected 5-year survival rate for all patients combined in whom lung cancer is diagnosed is 15 percent and by contrast, the 5-year survival rate for cases detected when the disease is still localized is 50 percent. At the present time, only 16 percent of lung cancer cases are diagnosed at this early stage.

Contact: John Cousins

(505) 821-0875


'/>"/>
SOURCE Biomoda, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Biomoda Announces Collaborative Agreement With New Mexico Tech
2. Biomoda, Inc. Retains MicroCap Management, LLC as its Lead Corporate Communications and Broker Relations Firm.
3. Biomoda Hires Manzano Strategies LLC to Spearhead Government Affairs Efforts
4. WallSt.net Announces Upcoming Interview With CEO of Biomoda
5. Ventria Expands Team and Hires Kansan as Director of Bioprocessing Operations
6. Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
7. MedImmune Announces Seven Key Promotions and New Hires
8. Diplomat Specialty Pharmacy Hires Vice President of Managed Markets
9. Valeritas Hires Senior Account Management Industry Expert for the Launch of the h-Patch(TM) Disposable Insulin Delivery Device
10. Phlo Affiliate Hires Chief Marketing Officer With Extensive Global Experience
11. Valeritas Hires Trade and Distribution Industry Expert for the Launch of the h-Patch(TM) Disposable Insulin Delivery Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , ... June 23, 2016 , ... ... quality, regulatory and technical consulting, provides a free webinar on Performing ... July 13, 2016 at 12pm CT at no charge. , Incomplete investigations are ...
(Date:6/23/2016)... 22, 2016  Amgen (NASDAQ: AMGN ) ... QB3@953 life sciences incubator to accelerate the development ... laboratory space at QB3@953 was created to help high-potential ... for many early stage organizations - access to laboratory ... Amgen launched two "Amgen Golden Ticket" awards, providing each ...
(Date:6/22/2016)... Cell Applications, Inc. and StemoniX announced ... up to one billion human induced pluripotent stem ... These high-quality, consistent stem cells enable researchers to ... more time doing meaningful, relevant research. This achievement ... process that produces affordable, reliable HiPSC for life ...
(Date:6/22/2016)... YORK , June 22, 2016  According ... growing next generation sequencing (NGS) market include significant ... of smaller sequencers.  More accessible and affordable sequencers, ... to growing demand for consumables including sample prep ... The Market for Sample Preparation for Next Generation ...
Breaking Biology Technology:
(Date:6/2/2016)... LONDON , June 2, 2016 ... Systems, Manned Platforms, Unmanned Systems, Physical Infrastructure, Support & ... intelligence provider visiongain offers comprehensive analysis of ... that this market will generate revenues of $17.98 billion ... Systems acquired DVTEL Inc, a leader in software and ...
(Date:5/16/2016)... NEW YORK , May 16, 2016   ... authentication solutions, today announced the opening of an IoT ... to strengthen and expand the development of embedded ... provides an unprecedented level of convenience and security with ... to authenticate one,s identity aside from DNA. EyeLock,s platform ...
(Date:4/28/2016)... India , April 28, 2016 ... Infosys (NYSE: INFY ), and Samsung SDS, a ... that will provide end customers with a more secure, ... services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... services, but it also plays a fundamental part in enabling ...
Breaking Biology News(10 mins):